Lilly’s proposed $1.4B acquisition of Point Biopharma gets investor pushback
Point has a pipeline of clinical and preclinical-stage compounds in development for the treatment of cancer using radiopharmaceutical isotopes that hold the promise of delivering targeted treatments to cancer patients.